Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitis
Elvira Mennillo, Yang Joon Kim, Gyehyun Lee, I Rusu, Ravi K. Patel, Leah C. Dorman, Emily Flynn, Stephanie Li, Jared L. Bain, Chris Andersen, Arjun A. Rao, Stanley Tamaki, Jessica Tsui, Alan Shen, Madison L. Lotstein, Maha K. Rahim, Mohammad Naser, Faviola Bernard-Vazquez, Walter L. Eckalbar, Soo‐Jin Cho, Kendall Beck, Najwa El‐Nachef, Sara Lewin, Daniel R. Selvig, Jonathan P. Terdiman, Uma Mahadevan, David Y. Oh, Gabriela K. Fragiadakis, Angela Oliveira Pisco, Alexis J. Combes, Michael G. Kattah
Abstract
Ulcerative colitis (UC) is driven by immune and stromal subsets, culminating in epithelial injury. Vedolizumab (VDZ) is an anti-integrin antibody that is effective for treating UC. VDZ is known to inhibit lymphocyte trafficking to the intestine, but its broader effects on other cell subsets are less defined. To identify the inflammatory cells that contribute to colitis and are affected by VDZ, we perform single-cell transcriptomic and proteomic analyses of peripheral blood and colonic biopsies in healthy controls and patients with UC on VDZ or other therapies. Here we show that VDZ treatment is associated with alterations in circulating and tissue mononuclear phagocyte (MNP) subsets, along with modest shifts in lymphocytes. Spatial multi-omics of formalin-fixed biopsies demonstrates trends towards increased abundance and proximity of MNP and fibroblast subsets in active colitis. Spatial transcriptomics of archived specimens pre-treatment identifies epithelial-, MNP-, and fibroblast-enriched genes related to VDZ responsiveness, highlighting important roles for these subsets in UC.